Scientist.com, the B2B marketplace for outsourced research and development (R&D) services, has partnered...
- Diaceutics invests in patient data to improve outcomes
- British universities must improve clinical trial reporting, says House of Commons
- Expert Insights: Moderna Therapeutics Barrels Ahead Towards Historic IPO
- Industry Viewpoints: Leveraging eSource in Data Management
- The Fundamentals Behind Effective Data Management
Scientist.com and Austrade to expand digital research marketplace in Australia
Scientist.com, the B2B marketplace for outsourced research and development (R&D) services, has partnered with Australian Trade and Investment Commission (Austrade).
Diaceutics invests in patient data to improve outcomes
Diaceutics has announced an investment of £1m ($1.1m) to expand and enhance its data lake by acquiring another 16 million patient records a year.
HMA publishes recommendations on complex clinical trials of personalised medicine
A subgroup of the EU’s Heads of Medicines Agencies (HMA) has published a set of common recommendations with regard to conducting complex clinical trials of personalised medicine.
British universities must improve clinical trial reporting, says House of Commons
The House of Commons Science and Technology Select Committee has announced that UK universities could be brought in for questioning if they fail to improve the transparency of their clinical trial procedure.
Report finds 800 UK university trials could become research waste
A new report by TranspariMED and Universities Allies for Essential Medicines UK has found that as many as 800 clinical trials by UK universities could become research waste as they violate reporting rules.
Industry Viewpoints: The Challenges of Clinical Data Management
In this Industry Viewpoint, Sarah Fal speaks to Kumar Komuravelli, Mallinckrodt Pharmaceuticals, on the arising technologies taking over the industry
Expert Insights: Moderna Therapeutics Barrels Ahead Towards Historic IPO
Paul Jeng, PhD, Infectious Diseases Analyst, GlobalData, analyzes Moderna Therapeutics’ growing stature as the young biotech punches above its weight